Disintegration of chemotherapy tablets for oral administration in patients with swallowing difficulties

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 2, 2013, Pages 145-150

  Siden, Rivka ^a   Wolf, Matthew ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

disintegration; Oral chemotherapy; oral syringe; safe administration; tablet crushing

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DASATINIB; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MITOTANE; TAP WATER; TIOGUANINE;

ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; DISINTEGRATION TESTING; DISPERSION; DYSPHAGIA; FEASIBILITY STUDY; HUMAN; PRIORITY JOURNAL; TABLET DISINTEGRATION; TABLET DISINTEGRATION TIME; TEMPERATURE DEPENDENCE; WATER TEMPERATURE;

DISINTEGRATION; ORAL CHEMOTHERAPY; ORAL SYRINGE; SAFE ADMINISTRATION; TABLET CRUSHING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DEGLUTITION DISORDERS; FEASIBILITY STUDIES; HUMANS; SOLUBILITY; SYRINGES; TABLETS; TEMPERATURE; TIME FACTORS; WATER;

EID: 84879294308     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212455446     Document Type: Article

References (14)

1. Lam MSH. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy. 2011 ; 31: 164-192
2. Chaffee BW, Armitstead JA, Benjamin BE, et al. Guidelines for the safe handling of hazardous drugs: consensus recommendations. Am J Health-Syst Pharm. 2010 ; 67: 1545-1546
3. Traynor K. Pediatric cancer chemotherapy formulations remain elusive. Am J Health-Syst Pharm. 2010 ; 67: 170-171
4. Gleevec (package insert). New Jersey: Novartis Pharmaceuticals Corporation ; 2002 :
5. National Institute for Occupational Safety and Health. NIOSH alert: preventing occupational exposure to anti-neoplastic and other hazardous drugs in health care settings. Available at: http://www.cdc.gov/niosh/docs/2004-165/ (accessed 12 June 2012)..
6. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006 ; 63: 1172-1193
7. Dupuis L, Armstrong M. Oral syringe for extemporaneously preparing doses. Am J Health-Syst Pharm. 1998 ; 55: 735-735
8. National Cancer Instituted. Patient/caregiver ad hoc education template. Available at: http://ctep.cancer.gov/protocolDevelopment/patient-caregiver- education.htm (accessed 9 October 2011)..
9. United States Pharmacopeia and National Formulary (USP 28-NF 23). Rockville, MD: United States Pharmacopeia Convention, 2005, pp. 2411-2412..
10. Methotrexate injection USP (package insert). Illinois: Hospira Inc. ; 2011 :
11. Busulfex injection (package insert). Ohio: Ben Venue Labs Inc. ; 2011 :
12. Cyclophosphamide for injection, USP (package insert). Illinois: Baxter Healthcare Corporation ; 2011 :
13. Sprycel (dasatinib) data on file. Princeton, NJ: Bristol-Myers Squibb ; 2012 :
14. Aliabadi HM, Romanick M, Somayaji V, et al. Stability of compounded thioguanine oral suspensions. Am J Health-Syst Pharm. 2011 ; 68: 900-908